Get started

SNY

Sanofi (SNY): A Strong Investment CaseCompany Overview: Sanofi NASDAQ:SNY is a major pharmaceutical company based in Paris, with a market capitalization of $134 billion. Investment Highlights: Dividend Yield: 3.8%, more than double the S&P 500 average. Drug Portfolio: Diverse and includes successful drug developments. Pipeline: Promising future drug pipeline with potential for growth. Berkshire Hathaway Investment: Long-standing investment from Berkshire Hathaway underscores the company’s attractiveness and stability. Outlook: We are bullish on SNY due to its growth potential and solid dividend payout. The combination of a strong drug portfolio, promising pipeline, and robust dividend makes Sanofi a compelling investment choice. #Sanofi #SNY #Pharmaceuticals #Investment #DividendYield #MarketCap #GrowthPotential #BerkshireHathaway #StockAnalysis #Bullish
NASDAQ:SNYLong
by Richtv_official
SNY Fib Levels On The Radar & WhySNY and TBIO buttoned up the news this morning sending a bunch of other biotech stocks running higher. Now that this is out of the way, levels could be important for longs looking for "what's next" and the 236 Fib level seems to be that area to watch. It was an area that the volatile SNY stock settled above for weeks and now is an area it hasn't been able to break above for the last several weeks. Heading into the month after this acquisition, it's gonna be interesting to see if mRNA stocks start to catch a bit more. " A mega buyout from Sanofi (NASDAQ: SNY) has investors looking at biotech stocks today. If you remember our article, “Top Biotech Penny Stocks On Robinhood To Watch This Week,” we discussed Sanofi and its strengthening relationship with a former penny stock, Translate Bio Inc. (NASDAQ: TBIO)...Sanofi had previously pledged to invest 400 million euros annually in a vaccines R&D facility to advance mRNA vaccines with Translate to benefit. Tuesday, Sanofi formally announced a $3.2 billion buyout of its vaccine collaboration partner. This was at $38 a share in cash, roughly 30% higher than the close on August 2nd. " Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NASDAQ:SNY
by PennyStocks101
Repatha will bring major volume and take AMGN to new heights.Repatha (AMGN) and Praluent (Regeneron (REGN)/Sinofy (SNY)) are two PCSK9 inhibitors, a new class of drugs to treat hypercholesterolemia more effectively than previously possible. This will trigger a HCV-like battle between the two as both have high efficacy. Both have room to share the market, allowing both to make a significant amount of money on these blockbuster drugs. Unlike the HCV battle where GILD had more than a year of first-to-market status, Praluent will only have a month of such status assuming REGN/SNY can capitalize on that extra time to quickly bring it to the US market faster than AMGN. However, Repatha is expected to hit the EU market sooner, so it's a fair tradeoff as both will be able to get some good traction. Additional difference could be in the pricing strategy of Praluent being cheaper due to lower dosing, however Repatha has a slightly higher efficacy (61% vs 56% Praluent) and has noted a possible 50% reduction in cardiovascular disease. If AMGN is able to prove these claims with a large post-marketing study, Repatha will have a significant advantage due to the added secondary benefit and can easily command a higher price point. Important Repatha Dates: June 10 ADCOM Aug 27 PDUFA Important Praluent Dates: June 9 ADCOM July 24 PDUFA MM's taking this down to $157 is a bargain given the strength of the company's overall pipeline. At the very least, we should see some action heading into the ADCOM dates and both drugs are expected to easily get positive recommendations. EMA has already given positive recommendations for both drugs in May. EMA approval for Repatha is expected in September, shortly after the FDA approval.
NASDAQ:AMGNLong
by Elemental
4